{
    "clinical_study": {
        "@rank": "111007", 
        "acronym": "REIN-MR", 
        "arm_group": [
            {
                "arm_group_label": "Active drug", 
                "arm_group_type": "Active Comparator", 
                "description": "Ranolazine therapy for three months"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sugar pill therapy for three months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether mitral regurgitation (or a leaky heart\n      valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve\n      after administration of ranolazine."
        }, 
        "brief_title": "Effect of Ranolazine on Valvular Disease in Patients With Pacemakers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Mitral Regurgitation", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Mitral Valve Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ischemic cardiomyopathy AND\n\n          -  Moderate or severe mitral regurgitation AND\n\n          -  Cardiac resynchronization therapy (CRT) \u2265 3 months prior to enrollment AND\n\n          -  Maximal Medical Therapy (ACE-Inhibitor, beta blocker, aldosterone antagonist,\n             diuretic, aspirin, statin)\n\n        Exclusion Criteria:\n\n          -  nonischemic cardiomyopathy\n\n          -  active heart failure\n\n          -  current ranolazine therapy\n\n          -  congenital heart disease\n\n          -  mechanical valve prostheses\n\n          -  vegetation/endocarditis\n\n          -  significant pulmonary disease\n\n          -  peripheral vascular disease\n\n          -  trivial or mild mitral regurgitation\n\n          -  creatinine clearance < 30 mL/min\n\n          -  liver cirrhosis\n\n          -  strong inhibitors of CYP3A (including ketoconazole, itraconazole, clarithromycin,\n             nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)\n\n          -  strong inducers of CYP3A (including rifampin, rifapentine, phenobarbital, phenytoin,\n             carbamazepine and St.John's wort)\n\n          -  Strong P-glycoprotein inhibitors (including cyclosporine, verapamil, and quinidine)\n\n          -  Initial QTc interval \u2265 440msec"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979965", 
            "org_study_id": "IN-US-259-0173"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active drug", 
                "description": "Ranolazine therapy for three months", 
                "intervention_name": "Ranolazine (Active drug)", 
                "intervention_type": "Drug", 
                "other_name": "Ranexa"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "description": "Placebo therapy for three months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mitral Regurgitation", 
            "cardiac resynchronization therapy", 
            "ranolazine", 
            "maximal medical therapy", 
            "ischemic cardiomyopathy"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "link": {
            "description": "University Cardiology", 
            "url": "http://utcardiology.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Knoxville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37920"
                }, 
                "name": "University Cardiology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy", 
        "other_outcome": {
            "measure": "Adverse Reactions", 
            "safety_issue": "Yes", 
            "time_frame": "T = 90 day"
        }, 
        "overall_official": {
            "affiliation": "University Cardiology", 
            "last_name": "Raj Baljepally, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "effective regurgitant orifice by echocardiography", 
                "safety_issue": "No", 
                "time_frame": "Day T = 90 days"
            }, 
            {
                "measure": "proximal isovelocity surface area by echocardiography", 
                "safety_issue": "No", 
                "time_frame": "T = 90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Seattle Angina Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "T = 0 days, and T = 90 days"
            }, 
            {
                "measure": "Rose Dyspnea Scale", 
                "safety_issue": "No", 
                "time_frame": "T = 0 days, and T= 90 days"
            }
        ], 
        "source": "University Cardiology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Cardiology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}